Binding molecules specific for HER3 and uses thereof

Patent metadata

Field	Value
Publication number	US-11091554-B2
Application number	US-201816024391-A
Country	US
Kind code	B2
Filing date	Jun 29, 2018
Priority date	Nov 23, 2011
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

First claim

What is claimed is:

1. An antibody or an antigen-binding fragment thereof, which specifically binds to human HER3 (Human Epidermal Growth Factor Receptor 3), comprising an antibody VL and an antibody VH, wherein the VL comprises the amino acid sequence:
[FW1]X 1 GSX 2 SNIGLNYVS(SEQ ID NO:49)[FW2]RNNQRPS(SEQ ID NO:21)[FW3]AAWDDX 3 X 4 X 5 GEX 6 (SEQ ID NO:50)[FW4]
wherein [FW1], [FW2], [FW3] and [FW4] represent VL framework regions, and wherein
(a) X 1 represents amino acid residues Arginine (R) or Serine (S),
(b) X 2 represents amino acid residues Serine (S) or Leucine (L),
(c) X 3 represents amino acid residues Serine (S) or Glycine (G),
(d) X 4 represents amino acid residues Leucine (L) or Proline (P),
(e) X 5 represents amino acid residues Arginine (R), Isoleucine (I), Proline (P) or Serine (S), and
(f) X 6 represents amino acid residues Valine (V) or Alanine (A), and
wherein the VH comprises the amino acid sequence:
[FW5]YYYMQ(SEQ ID NO:31)[FW6]X 7 IGSSGGVTNYADSVKG(SEQ ID NO:51)[FW7]VGLGDAFDI(SEQ ID NO:35)[FW8]
wherein [FW5], [FW6], [FW7] and [FW8] represent VH framework regions, and wherein X 7 represents amino acid residues Tyrosine (Y), Isoleucine (I) or Valine (V).

2. The antibody or antigen-binding fragment of claim 1 , wherein the VL comprises a complementarity determining region (CDR) 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 18, 19, and 20, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 21, a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 22, 23, 24, 25, 26, 27, 28, 29, and 30, and
wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 32, 33, and 34, a CDR3 comprising the amino acid sequence of SEQ ID NO: 35.

3. The antibody or antigen-binding fragment of claim 1 , which comprises a heavy chain constant region.

4. The antibody or antigen-binding fragment of claim 3 , wherein the heavy chain constant region is a human IgG constant region.

5. The antibody or antigen-binding fragment of claim 4 , wherein the human IgG constant region is an IgG1 constant region.

6. The antibody or antigen-binding fragment of claim 4 ,
(i) wherein the human IgG constant region comprises amino acid substitutions relative to a wild-type human IgG constant domain at positions 252, 254, and 256, wherein the numbering is according to the EU index as set forth in Kabat, and wherein
(a) the amino acid at position 252 (Methionine) is substituted with Tyrosine (Y),
(b) the amino acid at position 254 (Serine) is substituted with Threonine (T), and
(c) the amino acid at position 256 (Threonine) is substituted with Glutamic acid (E).

7. The antibody or antigen-binding fragment of claim 1 , which comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.

8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, a recombinant antibody, a multispecific antibody, or an antigen-binding fragment thereof; wherein the antigen-binding fragment is an Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, or sc(Fv)2; or wherein the antibody or antigen-binding fragment thereof is conjugated to at least one heterologous agent.

9. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.

10. A composition comprising the antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.

11. A kit comprising the antibody or antigen-binding fragment thereof of claim 1 .

12. A method of inhibiting the proliferation of a cell expressing human HER3 (Human Epidermal Growth Factor Receptor 3), said method comprising contacting the cell with the antibody or antigen-binding fragment of claim 1 .

13. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of claim 1 .

14. The method of claim 13 , wherein the cancer is selected from the group consisting of colon cancer, lung cancer, gastric cancer, breast cancer, head and neck cancer, and melanoma.

15. The method of claim 14 , wherein the cancer comprises cells comprising a KRAS mutation.

16. The method of claim 13 , wherein the cancer is characterized as expressing heregulin.

17. A method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a first agent which is the antibody or antigen-binding fragment thereof of claim 1 , in combination with a therapeutically effective amount of a second agent, which is an anti-cancer agent other than the first agent.

18. A method of diagnosing a human HER3 (Human Epidermal Growth Factor Receptor 3)-expressing cancer in a patient, wherein the method comprises the steps of:
(a) contacting a biological sample from the patient with the antibody or antigen-binding fragment of claim 1 ;
(b) detecting binding of the antibody or antigen-binding fragment to HER3 to determine a HER3 protein level in the biological sample from the patient; and
(c) comparing the HER3 protein level with a standard HER3 protein level.

19. A method of monitoring the human HER3 (Human Epidermal Growth Factor Receptor 3) protein level during treatment of a HER3-expressing cancer in a patient, wherein the method comprises the steps of:
(a) administering to the patient the antibody or antigen-binding fragment of claim 1 ;
(b) contacting a biological sample from the patient with the antibody or antigen-binding fragment;
(c) detecting binding of the antibody or antigen-binding fragment to HER3 to determine a HER3 protein level in the biological sample from the patient; and
(d) comparing the HER3 protein level with a standard HER3 protein level.

20. A method of monitoring human HER3 (Human Epidermal Growth Factor Receptor 3) protein activity level during treatment of cancer in a patient being administered the antibody or antigen-binding fragment of claim 1 , wherein the method comprises the steps of:
(a) contacting a biological sample from the patient with an antibody or antigen-binding fragment that specifically binds to phosphorylated HER3;
(b) detecting binding of the antibody or antigen-binding fragment to phosphorylated HER3 to determine a HER3 protein activity level in the biological sample from the patient; and
(c) comparing the HER3 protein activity level with a standard HER3 protein activity level.

Assignees

• Medimmune Llc

Inventors

• Chowdhury Partha S
• Tice David
• Xiao Zhan
• Steiner Philipp
• Kinneer Krista
• Rebelatto Marlon

Classifications

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/3053

  Skin, nerves, brain · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K2317/32

  specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title